Trial site
Agile Clinical Research Trials, LLC
Atlanta, Georgia 30328-5532, United StatesNot linked to an institution yet
- 9running trials
- 2closed trials
The trials here
What the 11 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 21 trial
- Phase 2/31 trial
- Status
- Recruiting6 trials
- Active, not recruiting3 trials
- Completed1 trial
- Terminated1 trial
- Lead sponsor
- Janssen Research & Development, LLC3 trials
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company2 trials
- Viridian Therapeutics, Inc.2 trials
- ACADIA Pharmaceuticals Inc.1 trial
- Bayer1 trial
- and 2 more
Running trials
Recruiting
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
NCT07573176· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745· Phase 3· Bristol-Myers Squibb· Source
Contact: Vasundhara Cheekati, Site 2611
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Contact: Vasundhara Cheekati, Site 1206
Active, not recruiting
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
NCT06625398· Phase 3· Viridian Therapeutics, Inc.· Source
Active, not recruiting
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
NCT06625411· Phase 3· Viridian Therapeutics, Inc.· Source
Recruiting
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673· Phase 2/3· ACADIA Pharmaceuticals Inc.· Source
Contact: Christine Murphy
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Contact: Vasundhara Cheekati, Site 1206
Active, not recruiting
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049· Phase 3· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error